USMLE Step 1 & 2 Common Solid Tumors: Lung, Breast, Colon, Prostate
Last updated: May 2, 2026
Common Solid Tumors: Lung, Breast, Colon, Prostate questions are one of the highest-leverage areas to study for the USMLE Step 1 & 2. This guide breaks down the rule, the elements you need to recognize, the named traps that catch most students, and a memory aid that scales to test day. Read it once, then practice the same sub-topic adaptively in the app.
The rule
Lung, breast, colon, and prostate cancers together account for the majority of US cancer deaths, and Step 2 CK rewards pattern recognition over esoteric pathology. For each tumor you must lock in three things: the demographic-plus-risk-factor profile that triggers suspicion, the guideline-driven screening test (LDCT, mammography, colonoscopy, PSA shared decision-making), and the stage-appropriate next best step (tissue diagnosis, staging imaging, definitive therapy, or palliation). When a vignette gives you a classic buzzword — apical mass with Horner syndrome, peau d'orange, iron-deficiency anemia in a 60-year-old man, or bone pain plus elevated alkaline phosphatase in an older man — your job is to match it to the right tumor and then pick the next correct action, not to over-order workup.
Elements breakdown
Lung cancer — non-small cell (NSCLC)
Adenocarcinoma, squamous cell, and large cell carcinomas; ~85% of lung cancers.
- Adeno: peripheral, non-smokers and women, EGFR/ALK mutations
- Squamous: central, cavitary, hypercalcemia via PTHrP
- Large cell: peripheral, poorly differentiated, aggressive
- Screening: annual LDCT ages 50–80, ≥20 pack-years, quit <15 yr
- Solitary pulmonary nodule >8 mm → PET/CT then biopsy
Common examples:
- Pancoast tumor causing Horner syndrome and shoulder pain
- Squamous cell with hypercalcemia and central cavitating mass
Lung cancer — small cell (SCLC)
Neuroendocrine tumor, ~15% of lung cancers, almost exclusively in smokers.
- Central, rapidly growing, early metastases
- Paraneoplastic: SIADH, ectopic ACTH, Lambert-Eaton
- Staged as limited vs extensive (not TNM in practice)
- Treatment: chemo + radiation; not surgical
- Strong association with heavy smoking
Breast cancer
Most common non-skin cancer in US women; lifetime risk ~12%.
- Risk: age, BRCA1/2, early menarche, late menopause, nulliparity
- Screening: biennial mammography ages 40–74 (USPSTF 2024)
- Palpable mass → diagnostic mammogram + US, then core biopsy
- Inflammatory: peau d'orange, dermal lymphatic invasion
- Receptors guide therapy: ER/PR (endocrine), HER2 (trastuzumab)
Common examples:
- BRCA1 carrier with triple-negative tumor
- Postmenopausal woman with ER+ tumor on aromatase inhibitor
Colorectal cancer
Adenocarcinoma arising from adenomatous polyps via APC/KRAS/p53 sequence.
- Right-sided: iron-deficiency anemia, occult bleeding, later obstruction
- Left-sided: change in caliber, hematochezia, obstruction earlier
- Screening: colonoscopy every 10 yr starting age 45 (USPSTF)
- Staging: CT chest/abd/pelvis + CEA; MRI pelvis for rectal
- Lynch (HNPCC), FAP — earlier and more aggressive screening
Common examples:
- Apple-core lesion on barium enema in 65-year-old
- Microsatellite instability tumor in young patient with Lynch
Prostate cancer
Adenocarcinoma of peripheral zone; most common non-skin cancer in US men.
- Often asymptomatic; found on PSA or DRE
- Bone metastases: osteoblastic, elevated alk phos, back pain
- Screening: shared decision-making PSA ages 55–69
- Diagnosis: transrectal US-guided biopsy, Gleason grading
- Localized: active surveillance, RP, or radiation; metastatic: ADT
Common examples:
- Older man with back pain and osteoblastic lesions on x-ray
- Hard nodule on DRE with PSA 12 ng/mL
Common patterns and traps
The Buzzword-to-Tumor Map
USMLE writers reach for a small, stable set of pathognomonic phrases: 'apple-core lesion' (left-sided colon), 'peau d'orange' (inflammatory breast), 'osteoblastic bone lesions in an older man' (prostate), 'cavitary central mass with hypercalcemia' (squamous lung), and 'apical mass with Horner syndrome' (Pancoast / NSCLC). Recognizing these on first read collapses a five-line vignette to a one-word diagnosis. The trap is that the same buzzword in a younger or atypical patient may point elsewhere — peau d'orange in a postpartum woman is more likely mastitis than IBC.
A choice that names the classically-associated tumor exactly, often phrased with the textbook adjective ('squamous cell carcinoma of the lung,' 'inflammatory breast carcinoma').
The Screening-vs-Diagnostic Confusion
Distractors will offer a screening test (mammography, LDCT, FOBT, repeat PSA in 6 months) when the patient already has symptoms or a palpable abnormality. Once a symptom or finding is present, the algorithm shifts to diagnostic imaging plus tissue. Picking the screening choice is the single most common mistake on solid-tumor vignettes.
An answer like 'screening mammography' for a patient with a palpable breast mass, or 'repeat PSA in 6 months' for a man with bone pain and PSA of 48.
The Premature-Treatment Trap
Choices that jump to definitive therapy — lumpectomy, prostatectomy, colectomy, lobectomy, or chemotherapy — before tissue diagnosis and staging. On Step 2 CK, you almost never treat without a histologic diagnosis and stage-defining imaging. The exception is true emergencies (cord compression, SVC syndrome with airway compromise) where stabilization precedes diagnosis.
An answer like 'radical prostatectomy' as the next step in a man with elevated PSA but no biopsy, or 'modified radical mastectomy' before core needle biopsy.
The Wrong-Modality Distractor
USMLE offers tests that sound reasonable but are wrong for the stage or tumor: PET-CT before tissue diagnosis, CT abdomen for breast staging in a low-risk patient, brain MRI for asymptomatic colon cancer, or bone scan in a patient with no skeletal symptoms and a low-Gleason prostate cancer. The right modality follows the algorithm; ordering 'more imaging' is not a free pass.
An answer like 'PET-CT' for a 1.0 cm screen-detected breast cancer, or 'whole-body MRI' as part of routine colon cancer staging.
The Tumor-Marker Misuse
CEA, CA 15-3, CA 19-9, AFP, and PSA are mostly surveillance and prognostic tools, not diagnostic. A normal CEA does not rule out colon cancer; a mildly elevated PSA does not by itself diagnose prostate cancer. Distractors will offer 'check CEA' or 'CA 15-3' as the next step in working up a new mass — almost always wrong.
An answer like 'order CEA level' as the next diagnostic step in a patient with a colonic mass on imaging, instead of colonoscopy with biopsy.
How it works
Picture Mr. Alvarez, a 68-year-old with a 40-pack-year history who quit 8 years ago, presenting with a 2.4 cm right upper lobe spiculated mass found incidentally on a chest CT done for chest trauma. Your first move is not to call thoracic surgery — it is to obtain a PET/CT to assess for metastatic disease and mediastinal nodal involvement, followed by tissue diagnosis (CT-guided biopsy if peripheral, EBUS if central or nodal). The screening eligibility (50–80, ≥20 pack-years, quit <15 years) is itself a high-yield Step 2 CK fact, but in this vignette he already has a lesion, so you are past screening and into staging. Contrast that with Ms. Patel, a 52-year-old with a new 1.5 cm fixed breast mass: diagnostic mammogram + ultrasound first, then core needle biopsy — never excisional biopsy as the initial diagnostic step, and never reassurance based on a normal screening mammogram from last year. For Mr. Chen, a 62-year-old man with a hemoglobin of 9.1 g/dL and MCV 72 fL on routine labs, the answer is colonoscopy, because iron-deficiency anemia in a man or postmenopausal woman is colon cancer until proven otherwise. And for Mr. Williams, a 70-year-old with new low back pain, a PSA of 48 ng/mL, and osteoblastic lesions on plain films — the diagnosis is metastatic prostate cancer, the next step is prostate biopsy plus a bone scan, and the treatment lever is androgen deprivation therapy.
Worked examples
Which of the following is the most appropriate next step in management?
- A Reassure him that he is past the window for lung cancer screening because he quit more than 5 years ago
- B Obtain a chest x-ray annually for the next 5 years
- C Order annual low-dose chest CT for lung cancer screening ✓ Correct
- D Order sputum cytology every 6 months
Why C is correct: USPSTF (2021) recommends annual low-dose CT (LDCT) screening for adults aged 50–80 with a ≥20-pack-year smoking history who currently smoke or have quit within the past 15 years. Mr. Alvarez is 68, has 40 pack-years, and quit 8 years ago — he meets every criterion. LDCT has been shown to reduce lung-cancer mortality compared with chest x-ray in the NLST and NELSON trials.
Why each wrong choice fails:
- A: The cutoff is 15 years since quitting, not 5; he is squarely within the eligibility window. (The Screening-vs-Diagnostic Confusion)
- B: Chest x-ray was the comparator arm in the NLST trial and did not reduce lung-cancer mortality; LDCT is the guideline-endorsed modality. (The Wrong-Modality Distractor)
- D: Sputum cytology has poor sensitivity for early-stage lung cancer and is not recommended for screening. (The Wrong-Modality Distractor)
Which of the following is the most appropriate next step in evaluation?
- A Reassure her given the negative mammogram 10 months ago and re-examine in 3 months
- B Diagnostic mammography and targeted breast ultrasound, followed by core needle biopsy if a mass is confirmed ✓ Correct
- C Excisional biopsy of the mass without further imaging
- D Order a serum CA 15-3 level
Why B is correct: A new palpable breast mass requires triple assessment: clinical exam, imaging (diagnostic mammogram plus targeted ultrasound — ultrasound is especially useful in younger women with dense breasts), and tissue diagnosis via core needle biopsy if a discrete lesion is confirmed. A recent normal screening mammogram does not rule out a clinically significant mass; screening and diagnostic mammography are different studies with different protocols and indications.
Why each wrong choice fails:
- A: A negative screening mammogram does not exclude a palpable mass; deferring evaluation risks missing an interval cancer. (The Screening-vs-Diagnostic Confusion)
- C: Core needle biopsy, not excisional biopsy, is the standard initial diagnostic step — it preserves tissue planes for definitive surgery and provides receptor status. (The Premature-Treatment Trap)
- D: CA 15-3 is a surveillance marker for known breast cancer, not a diagnostic test for a new mass. (The Tumor-Marker Misuse)
Which of the following is the most appropriate next step in management?
- A Begin androgen deprivation therapy with leuprolide immediately
- B Initiate radical prostatectomy referral
- C Transrectal ultrasound-guided prostate biopsy and bone scan for staging ✓ Correct
- D MRI lumbar spine and start high-dose dexamethasone for cord compression
Why C is correct: This patient almost certainly has metastatic prostate adenocarcinoma — older man, osteoblastic bone lesions, markedly elevated PSA, hard prostate nodule, and elevated alkaline phosphatase reflecting bone turnover. However, definitive management requires histologic confirmation via prostate biopsy plus formal staging with a bone scan (and often CT of the abdomen/pelvis) before committing to systemic therapy. He has back pain but a non-focal neurologic exam and no red flags for cord compression, so emergent imaging plus steroids is not yet indicated.
Why each wrong choice fails:
- A: ADT is the right treatment for confirmed metastatic prostate cancer, but you do not start it before tissue diagnosis and staging — biopsy first. (The Premature-Treatment Trap)
- B: Radical prostatectomy is a localized-disease therapy; in clearly metastatic disease it is not curative and not offered as initial management, and you still need a tissue diagnosis first. (The Premature-Treatment Trap)
- D: Cord compression workup is reserved for patients with neurologic deficits, saddle anesthesia, bowel/bladder dysfunction, or progressive weakness; this patient has none of those, so empiric steroids and emergent MRI are not indicated. (The Wrong-Modality Distractor)
Memory aid
"LBC-P, Screen-Stage-Step": Lung (LDCT) → Breast (mammogram) → Colon (colonoscopy) → Prostate (PSA, shared decision). For any vignette: ① identify the tumor by buzzword, ② confirm with the right test, ③ stage before treating. Bonus mnemonic for prostate mets: "Old man, Bone pain, Big PSA, Blastic lesions" = the four B's of metastatic prostate cancer.
Key distinction
The hardest line to draw is between "order screening" and "order diagnostic workup." Screening tests (LDCT, mammogram, colonoscopy, PSA discussion) apply to asymptomatic average-risk patients within the guideline age windows. The moment the vignette includes a symptom (hemoptysis, palpable mass, hematochezia, bone pain), screening guidelines no longer apply — you owe the patient diagnostic imaging plus tissue, not a repeat screen.
Summary
Match the demographic-plus-symptom pattern to one of the big four tumors, apply the correct screening rule only when the patient is asymptomatic, and otherwise advance to diagnostic imaging and tissue biopsy before committing to any therapy.
Practice common solid tumors: lung, breast, colon, prostate adaptively
Reading the rule is the start. Working USMLE Step 1 & 2-format questions on this sub-topic with adaptive selection, watching your mastery score climb in real time, and seeing the items you missed return on a spaced-repetition schedule — that's where score lift actually happens. Free for seven days. No credit card required.
Start your free 7-day trialFrequently asked questions
What is common solid tumors: lung, breast, colon, prostate on the USMLE Step 1 & 2?
Lung, breast, colon, and prostate cancers together account for the majority of US cancer deaths, and Step 2 CK rewards pattern recognition over esoteric pathology. For each tumor you must lock in three things: the demographic-plus-risk-factor profile that triggers suspicion, the guideline-driven screening test (LDCT, mammography, colonoscopy, PSA shared decision-making), and the stage-appropriate next best step (tissue diagnosis, staging imaging, definitive therapy, or palliation). When a vignette gives you a classic buzzword — apical mass with Horner syndrome, peau d'orange, iron-deficiency anemia in a 60-year-old man, or bone pain plus elevated alkaline phosphatase in an older man — your job is to match it to the right tumor and then pick the next correct action, not to over-order workup.
How do I practice common solid tumors: lung, breast, colon, prostate questions?
The fastest way to improve on common solid tumors: lung, breast, colon, prostate is targeted, adaptive practice — working questions that focus on your specific weak spots within this sub-topic, getting immediate feedback, and revisiting items you missed on a spaced-repetition schedule. Neureto's adaptive engine does this automatically across the USMLE Step 1 & 2; start a free 7-day trial to see your sub-topic mastery climb in real time.
What's the most important distinction to remember for common solid tumors: lung, breast, colon, prostate?
The hardest line to draw is between "order screening" and "order diagnostic workup." Screening tests (LDCT, mammogram, colonoscopy, PSA discussion) apply to asymptomatic average-risk patients within the guideline age windows. The moment the vignette includes a symptom (hemoptysis, palpable mass, hematochezia, bone pain), screening guidelines no longer apply — you owe the patient diagnostic imaging plus tissue, not a repeat screen.
Is there a memory aid for common solid tumors: lung, breast, colon, prostate questions?
"LBC-P, Screen-Stage-Step": Lung (LDCT) → Breast (mammogram) → Colon (colonoscopy) → Prostate (PSA, shared decision). For any vignette: ① identify the tumor by buzzword, ② confirm with the right test, ③ stage before treating. Bonus mnemonic for prostate mets: "Old man, Bone pain, Big PSA, Blastic lesions" = the four B's of metastatic prostate cancer.
What's a common trap on common solid tumors: lung, breast, colon, prostate questions?
Ordering excisional biopsy before core biopsy for a breast mass
What's a common trap on common solid tumors: lung, breast, colon, prostate questions?
Choosing CEA as a diagnostic test instead of using it for surveillance
Ready to drill these patterns?
Take a free USMLE Step 1 & 2 assessment — about 25 minutes and Neureto will route more common solid tumors: lung, breast, colon, prostate questions your way until your sub-topic mastery score reflects real improvement, not luck. Free for seven days. No credit card required.
Start your free 7-day trial